Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 15/20 | 1.00 |
| ▸ | GRPR | P30550 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.42 |
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809992 | 0.82 | NMBR (1.00) | NMBRGRPRBCHETP53MAPT | |
| SCHEMBL7671985 | 0.78 | NMBR (0.65) | NMBRGRPRBCHEMAPTMMP2 | |
| SCHEMBL6181433 | 0.77 | NMBR (1.00) | NMBRGRPRBCHEMMP9MMP8 | |
| SCHEMBL6809988 | 0.76 | NMBR (0.80) | NMBRGRPRBCHETP53MAPT | |
| SCHEMBL8574758 | 0.76 | NMBR (0.75) | NMBRGRPRBCHE | |
| SCHEMBL6250669 | 0.75 | NMBR (1.00) | NMBRGRPR | |
| SCHEMBL6181007 | 0.75 | NMBR (1.00) | NMBRGRPR | |
| SCHEMBL6180485 | 0.73 | NMBR (0.75) | NMBRGRPR | |
| SCHEMBL9680304 | 0.71 | MAPT (0.58) | NMBRGRPRTP53MAPTSOS1 | |
| SCHEMBL9679325 | 0.71 | NMBR (0.55) | NMBRGRPRTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0920424-B1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | claimed |
| EP-1333824-B1 | TREATMENT OF SEXUAL DYSFUNCTION WITH BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | claimed |
| EP-1333824-A2 | TREATMENT OF SEXUAL DYSFUNCTION | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020169101-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | claimed |
| WO-2002040008-A2 | TREATMENT OF SEXUAL DYSFUNCTION WITH NON PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | claimed |
| US-6194437-B1 | ANTIDEPRESSANTS; ANTICANCER AGENTS; GASTROINTESTINAL DISORDERS; COGNITION ACTIVATORS | WARNER-LAMBERT COMPANY | 2001-02-27 | — | — | US | claimed |
| EP-0920424-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-06-09 | — | — | EP | claimed |
| WO-1998007718-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-26 | — | — | WO | claimed |
| EP-0920424-B1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1333824-B1 | TREATMENT OF SEXUAL DYSFUNCTION WITH BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040087561-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY LLC | 2004-05-06 | — | — | US | disclosed |
| EP-1333824-A2 | TREATMENT OF SEXUAL DYSFUNCTION | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1333829-A1 | TREATMENT OF SEXUAL DYSFUNCTION USING BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020169101-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | disclosed |
| WO-2002040008-A2 | TREATMENT OF SEXUAL DYSFUNCTION WITH NON PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002040022-A1 | TREATMENT OF SEXUAL DYSFUNCTION USING BOMBESIN ANTAGONIST | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | disclosed |
| US-20020058606-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-05-16 | — | — | US | disclosed |
| US-6194437-B1 | ANTIDEPRESSANTS; ANTICANCER AGENTS; GASTROINTESTINAL DISORDERS; COGNITION ACTIVATORS | WARNER-LAMBERT COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-0920424-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998007718-A1 | NON-PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058606-A1 | Treatment of sexual dysfunction | BRS3, GNRHR, VIPR2 | NMBR 122/4885GRPR 8/4885BCHE 180/4885 |
| US-20040087561-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | NMBR 258/4885GRPR 199/4885BCHE 49/4885 |
| US-20020169101-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | NMBR 258/4885GRPR 199/4885BCHE 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.